Orgenesis Inc. (ORGS)
OTCMKTS · Delayed Price · Currency is USD
0.7100
+0.3100 (77.50%)
At close: Jul 31, 2026
Orgenesis Financials Overview
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Revenue Revenue Growth | 1.04 | 1.04 | 0.53 | 36.03 | 35.5 | 7.65 |
Revenue Growth | 95.28% | 95.28% | -98.53% | 1.47% | 363.96% | 96.25% |
Gross Profit Gross Profit Growth | -0.89 | -0.89 | -5.73 | 30.89 | 35.5 | 7.65 |
Operating Income Operating Income Growth | -26.02 | -26.02 | -52.2 | -7.54 | -16.8 | -95.1 |
Net Income Net Income Growth | -48.17 | -48.17 | -55.36 | -14.89 | -18.05 | 6.27 |
Earnings Per Share EPS Growth | -11.44 | -11.44 | -19.08 | -5.93 | -7.44 | 2.94 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Octomera Octomera Growth | 0.53 | 0.53 | 0.07 | 35.17 | 35.07 |
Therapies Therapies Growth | 0.53 | 0.53 | 0.52 | 6.43 | 11.93 |
Eliminations Eliminations Growth | -0.02 | -0.02 | -0.05 | -5.58 | -11.49 |
Total Total Growth | 1.04 | 1.04 | 0.53 | 36.03 | 35.5 |
| Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Investments Cash & Investments Growth | 0.08 | 0.08 | 0.84 | 5.31 | 5.47 | 44.92 |
Total Debt Total Debt Growth | 18.26 | 18.26 | 22.62 | 20.27 | 11.84 | 12.91 |
Net Cash (Debt) Net Cash Growth | -18.18 | -18.18 | -21.78 | -14.96 | -6.37 | 32.02 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -4.32 | -4.32 | -7.51 | -5.96 | -2.62 | 15.02 |
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Cash Flow Operating Cash Flow Growth | -17.08 | -17.08 | -14.84 | -24.92 | -26.87 | -78.05 |
Capital Expenditures CapEx Growth | -0.26 | -0.26 | -2.1 | -12.42 | -7.87 | -1.53 |
Free Cash Flow Free Cash Flow Growth | -17.34 | -17.34 | -16.93 | -37.34 | -34.73 | -79.57 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Gross Margin | -86.28% | -86.28% | - | 85.75% | 100.00% | 100.00% |
Operating Margin | -2513.53% | -2513.53% | -9849.62% | -20.93% | -47.32% | -1242.85% |
Pretax Margin | -4726.18% | -4726.18% | -12159.43% | -33.20% | -50.56% | -1264.19% |
Profit Margin | -4653.62% | -4653.62% | -10445.47% | -41.33% | -50.85% | 81.94% |
FCF Margin | -1675.27% | -1675.27% | -3194.91% | -103.65% | -97.83% | -1039.87% |
| Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
PE Ratio | - | - | - | - | - | 17.34 |
Forward PE | - | 0.94 | 0.94 | 9.29 | - | - |
PS Ratio | 6.72 | 9.44 | 30.12 | 1.38 | 1.97 | 14.21 |